Weekly Life Science News Round Up: 13th – 17th June

Written by: Editor
Published on: 17 Jun 2022

Weekly Life Science News Round-UpA round up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Devices sectors from 13th-17th June.

Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron

Sanofi reports data from two trials, VAT02 Cohort 2 and COVIBOOST VAT013, conducted with its new next-generation COVID-19 booster vaccine candidate modelled on the Beta variant antigen and including GSK’s pandemic adjuvant.

Evotec enters a drug discovery collaboration with Janssen

Under the agreement, Evotec and Janssen will jointly conduct screens on the identified targets and collaborate with hit identification and lead optimisation of the most promising chemical assets, leveraging Evotec’s end-to-end integrated drug discovery and development platform.

Boehringer Ingelheim signs option to Acquire Trutino Biosciences

Boehringer Ingelheim announces the signing of an option to acquire Trutino Biosciences Inc., a San Diego-based biotech company.

New laboratories for growing Nottingham CRO Cellomatics Biosciences

Leading contract research organisation (CRO) Cellomatics Biosciences has moved into new purpose-built premises in Nottingham in the wake of rising demand for its bespoke preclinical and early drug discovery phase laboratory services.

Parexel expands patient access to clinical trials through new Community Alliance Network

Parexel announces the launch of its Community Alliance Network, a novel program further integrating clinical research into the community healthcare setting to better service patients and in turn create further opportunity for increased diversity in clinical trials.

NOXXON enters into collaboration with US National Cancer Institute to characterize effects of lead compounds on brain tumors

NOXXON Pharma N.V. announces that it has entered into a material transfer agreement with the U.S. National Cancer Institute (NCI), of the National Institutes of Health (NIH), to further explore the effects of NOXXON’s lead compounds on brain tumors.

Gerresheimer partners with MedTech start-up Adamant Health to revolutionize treatment of Parkinson’s disease

Gerresheimer AG and the Finnish MedTech start-up Adamant Health Oy partner up to develop a life-changing solution for millions of people worldwide suffering from Parkinson’s disease.

Happify Health and Almirall go live with digital solution to support psoriasis patients

Happify Health and Almirall S.A. announce that Claro, a digital program developed via the innovative partnership of both companies, is live and now available to people with psoriasis in Spain, Italy and the United Kingdom.

Oxford BioTherapeutics announces research collaboration with ImmunoGen to develop novel antibody-drug conjugates

Oxford BioTherapeutics announce a multi-year collaboration to research, develop and commercialize novel, first-in-class ADCs with ImmunoGen (IMGN), a leader in the expanding field of ADCs for the treatment of cancer.

Genomics England will anchor Canary Wharf life science cluster

Genomics England Limited will move its headquarters to Canary Wharf this autumn, as part of the development of a major life science cluster. Genomics England will move into One Canada Square, giving the company a world-class platform for growth and collaboration in developing life sciences community at Canary Wharf.

Beckley Psytech announces partnership with Ksana Health, building on digital strategy to deliver optimised patient outcomes

Beckley Psytech and Ksana Health announce that the companies have entered into a partnership to support the collection and analysis of digital behavioural data in Beckley Psytech’s future clinical trials.

Banook group continues global expansion with US office opening

The Banook Group, specialized in cardiac safety, clinical imaging, and endpoint adjudication, today announces the opening of its fist US office in Boston, Massachusetts. This is the third international office for Banook since its inception in 1999.

Generis celebrates new milestones as swathes of the global pharma industry default to CARA Life Sciences™ to manage critical data and content

Generis has announced more impressive milestones as the international life sciences industry spearheads rapid adoption of the one-stop, unified, cloud-based platform for managing critical data, content and business processes across multiple functions.